Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

22.75 -0.31 (-1.34%)
Delayed Quote Updated: 2:57 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 37.3% Share Drop
From Kirby McInerney LLP
Via Business Wire
News headline image
uniQure BLA Filed as AMT-130 Shows 4-Year Huntington’s Functional Benefit ↗
uniQure (NASDAQ:QURE) reported updated Phase I/II data for its investigational Huntington’s disease gene therapy, ifezuntirgene inilparvovec, or AMT-130, including 36-month results from all high-dose... 
Via MarketBeat
Top movers analysis one hour before the close of the markets on 2026-09-29: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
UniQure (NASDAQ:QURE) Rises on Pipeline Progress Despite Wider Q2 Loss ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
News headline image
QURE Investor Alert: uniQure Securities Investigation - Kehoe Law Firm, P.C.
From Kehoe Law Firm
Via GlobeNewswire
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Tuesday. ↗
Via Chartmill
News headline image
uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure (QURE) Q2 2026 Earnings Call Transcript ↗
Gene therapy biotech secures FDA alignment for Huntington's disease BLA submission. 
Via The Motley Fool
Topics Earnings
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million. uniQure... 
Via Benzinga
News headline image
uniQure Q2 Earnings Call Highlights ↗
uniQure (NASDAQ:QURE) said it has aligned with the U.S. Food and Drug Administration on a potential accelerated-approval pathway for AMT-130, its investigational gene therapy for Huntington's disease,... 
Via MarketBeat
Topics Earnings
News headline image
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure to Announce Second Quarter 2026 Financial Results
~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~ 
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Pricing of Upsized $225 Million Public Offering
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces $150 Million Proposed Public Offering
From uniQure Inc.
Via GlobeNewswire
News headline image
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s.... 
Via InvestorPlace
News headline image
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
From uniQure Inc.
Via GlobeNewswire
Top movers in Wednesday's session ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
Gapping stocks in Wednesday's session ↗
Via Chartmill
Discover the top movers in Wednesday's pre-market session. ↗
Via Chartmill
News headline image
uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure to Announce First Quarter 2026 Financial Results
From uniQure Inc.
Via GlobeNewswire
News headline image
QURE CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.